Weber W, Knipper W, Hugo K
Urologe A. 1977 May;16(3):190-2.
Advanced bladder carcinoma still has a poor prognosis. While the five-year-survival in stage T1N0M0 is about 80%, less than 50% of the patients in stage T2N0M0 survive 5 years. This prognosis could not be altered by a more radical operation or by radiation therapy. Therefore we started postoperative adjuvant chemotherapy in 1972. First we tested the effect of three different cytostatic drug therapy schedules. Although successful treatment was achieved in several cases, there were other patients who did not respond to one of the three therapy schedules. We then started applying all three schedules, one after the other, in intervals of 4 weeks. Therapeutic procedure now is: After diagnosis by cystoscopy and histology and TNM-classification, urologic therapy is performed (electroresection, cystectomy, etc.). Then in stage T2-4N0-1M0-1 postoperative adjuvant chemotherapy follows. Thus far, we have achieved complete remission in all patients except one (after radiation therapy). No definite comments as to survival can be made at this time.
晚期膀胱癌的预后仍然很差。T1N0M0期患者的五年生存率约为80%，而T2N0M0期患者的五年生存率不到50%。更激进的手术或放射治疗并不能改变这种预后。因此，我们在1972年开始了术后辅助化疗。首先，我们测试了三种不同的细胞毒性药物治疗方案的效果。虽然在一些病例中取得了成功治疗，但也有其他患者对这三种治疗方案中的一种没有反应。然后，我们开始依次每隔4周应用这三种方案。现在的治疗程序是：在通过膀胱镜检查、组织学检查和TNM分类确诊后，进行泌尿外科治疗（电切术、膀胱切除术等）。然后，对于T2-4N0-1M0-1期患者，术后进行辅助化疗。到目前为止，除了一名患者（放疗后）外，我们已使所有患者实现完全缓解。目前对于生存率还无法给出确切评价。
